

EPHAR2024

The Federation of European Pharmacological Societies

9th European Congress of Pharmacology



FINAL PROGRAM

23-26
June
2024

**ATHENS
GREECE**

Megaron Athens
International
Conference Centre

ephar2024.org

Professional Congress
Organizer:



CONVIN S.A.
29 K. Varnali str,
15233 Chalandri
Athens, Greece
+30210 6833600
www.convin.gr

Welcome Address

Welcome Letter

The **Federation of European Pharmacological Societies** (EPHAR) consists of 29 member societies that collectively have a total of 12,000 individual members across Europe. Eight years after its last in person Congress, EPHAR will welcome pharmacologists from Europe and the world from **June 23-26, 2024** at the **Megaron Athens International Conference Center**, in downtown Athens. We look forward to hosting a diverse crowd of students, early career researchers, as well as late stage accomplished professionals and world-leading authorities. We anticipate the active participation of basic and clinical pharmacologists from academia, as well as biotech innovators and pharma industry scientists.

There is a number of opportunities to get involved with EPHAR2024. We will be accepting abstracts submissions for oral communications and poster presentations until December 2023 and we invite proposals for satellite meetings until January 2024. The scientific sessions at EPHAR2024 include keynote lectures, round tables, panel discussions, workshops, as well as oral and poster sessions, where you can share your expertise and experiences with other attendees. The conference presents a unique opportunity for intra- and interdisciplinary cross-fertilization of ideas and incorporation of new approaches in all areas of drug discovery and development from target identification and validation to clinical science.

We are looking forward to welcoming you to Greece a country famed for its history, its natural beauty and its hospitality. You will be able to taste some of Greece's ancient and modern culture, while catching up with friends and colleagues, in the events in our social program.

With Best Wishes,



Andreas Papapetropoulos, PhD
EPHAR President

Organizers

About EPHAR



Established in 1990, the **Federation of European Pharmacological Societies**, a non-profit association, set as its mission to advance research and education in Pharmacology and related sciences and to promote co-operation between National/Regional Pharmacological Societies in Europe and surrounding countries. Fundamental principle of EPHAR is that nothing done by, or in the name of, the federation shall detract from autonomy of any of the participating societies. As to achieve its objects, the Federation undertakes the follow actions:

- ✓ Hold and arrange instructional courses and training programs in matters connected with pharmacology;
- ✓ Facilitate the exchange of scientific information between European pharmacologists by encouraging the holding of joint meetings between European member societies and by other appropriate means, like the periodical European congresses of pharmacology;
- ✓ Collect, disseminate information and encourage the participation to important activities organized by member societies. This will include the production of a calendar of the National and joint meetings of each European society;
- ✓ Establish common standards for basic courses in pharmacology;
- ✓ Encourage scientific collaboration between member societies by appropriate means.

About HSBCP



The Hellenic Society of Basic and Clinical Pharmacology is a non-profit scientific society which, for the last three decades, has been supporting the dissemination and advancement of the science of Pharmacology in Greece. The Society's aims include informing, supporting, and promoting scientists in the fields of basic and clinical pharmacology, be it at research or service providing level, as well as the promotion of scientific associations and collaborations, in Greece and abroad.

The Society organizes congresses, meetings and seminars and participates actively in international scientific events concerning Pharmacology in general, taking particular consideration of its younger scientist - members.

The Society is a full member of the Federation of European Pharmacological Societies (EPHAR), the International Union of Basic and Clinical Pharmacology (IUPHAR) and the European Association for Clinical Pharmacology and Therapeutics (EACPT), with official representation in working groups and executive committees.

The Society believes at the great potential of the science of Pharmacology and of its contribution to national development, while it welcomes the support and contribution of all interested parties in achieving its aims.

Scientific Program

Sunday, June 23, 2024

12:00-14:00 | *MC3 Hall*

INDUSTRY SESSION: Cannabidiols, the Westward Movement of Botanicals

Sponsored by Vectura Fertin Pharma

Chairs: A. Wallace Hayes, Julia Hoeng

- | | |
|-------------|---|
| 12:00-12:20 | The Value of Biosynthetic Cannabinoids for Drug Development
Zohar Koren |
| 12:20-12:40 | Sustainable Operating Model of Medical Cannabis in Thailand
Pornchai Padmindra |
| 12:40-13:00 | Safety of Cannabidiols
Blaine Philips |
| 13:00-13:20 | Cannabidiol as a Mainstream Medicine: Beyond Dravet and Lennox-Gastaut
Peter Pressman |
| 13:20-13:40 | Therapeutic Prospects of Cannabinoids in the Immunomodulation of Prevalent Autoimmune Disease
Sandra Santander González |
| 13:40-14:00 | The Anti-Inflammatory/Wound Healing Effects of CBD and Thai Traditional Medicine
Sakan Warinhomhoun |

14:00-15:00 Opening Ceremony | *Trianti Hall*

15:00-16:00 Plenary 1 | *Trianti Hall*

Chairs: Clive Page, Andreas Papapetropoulos

Understanding Migraine and Developing New Therapies: Bench to Bedside
Peter Goadsby

16:00-16:30 Break

16:30-18:00 | MC3 Hall

Advancements in Longevity Pharmacology: Bridging Animal Models and Human Healthspan

Organized by the Portuguese Society of Pharmacology

Chairs: Claudia Cavadas, Maria José Diógenes

- | | |
|-------------|---|
| 16:30-17:00 | Pharmacological interventions with potential for extending human healthspan
Claudia Cavadas |
| 17:00-17:30 | Future directions of longevity pharmacology research
João Pedro Magalhães |
| 17:30-18:00 | Round Table and Discussion |

16:30-18:30 | Trianti Hall

Pharmacogenomics and Personalized Medicine

Organized by the European Society of Pharmacogenomics and Personalized Therapy

Chairs: Vangelis Manolopoulos, Sanja Stankovic

- | | |
|-------------|--|
| 16:30-16:50 | Pharmacogenomics of HLA-Related Adverse Drug Reactions
Ann K. Daly |
| 16:50-17:10 | Implementation of Pharmacogenetics in Health Systems: a View from European Regulation and the Example of Incorporation in Spain
Adrián Llerena |
| 17:10-17:30 | Pharmacogenomics and Endogenous Biomarkers for OATP1B1
Mikko Niemi |
| 17:30-17:50 | Omics Approaches for Personalization of Anticoagulant Drug Therapy
Georgia Ragia |
| 17:50-18:10 | Optimizing Drug Therapy using a DNA-Passport for Medication
Ron H.N. van Schaik |
| 18:10-18:30 | Discussion |

18.30 Welcome Reception | Musses Foyer

Monday, June 24, 2024

09:00-09:45 Keynote | MC3 Hall

Chairs: Antonis Goulas, Eeva Moilanen

Multi- and poly-pharmacology of carbonic anhydrase inhibitors

Claudiu Supuran

09:00 - 09:45 Keynote | Trianti Hall

Chairs: Giuseppe Cirino, Maria Diógenes

Targeting neurotrophin receptors in Alzheimer's Disease

Achilleas Gravanis

09:45-10:15 Coffee Break

10:15-12:15 | MC3 Hall

Erectile Dysfunction: Mechanisms and Therapeutic Strategies: State of the Art

Organized by the Basic & Clinical Pharmacology & Toxicology Journal

Chairs: Francisco Pérez Vizcaíno, Ulf Simonsen

10:15-10:45 The role of hydrogen sulfide pathway in erectile dysfunction

Roberta d'Emmanuele di Villa Bianca

10:45-11:15 Erectile dysfunction induced by Vitamin D deficiency and alcoholism

Francisco Pérez Vizcaíno

11:15-11:45 Modulation of dopaminergic pathways to treat sexual dysfunction

Ulf Simonsen

11:45-12:15 The Impact of Empagliflozin in Diabetic Erectile Dysfunction: H₂S-Mediated Benefits

Gulcan Demir

10:15-12:15 | Trianti Hall

Molecular Insights into Signal Transduction of G Protein-Coupled Receptors

Organized by the German Society for Pharmacology

Chairs: Christoph Klenk, Constantine Tamvakopoulos

- | | |
|-------------|---|
| 10:15-10:35 | Novel insights into the function and inhibition of intrinsically β -arrestin-biased 7TM receptors
Andy Chevigne |
| 10:35-10:55 | Genetic code expansion for structural and dynamic studies of GPCRs in living cells
Irene Coin |
| 10:55-11:15 | Exploiting data-driven approaches to facilitate G protein-coupled receptor pharmacology
Assoc. Alexander Hauser |
| 11:15-11:35 | The elusive pharmacology of the Super Conserved Receptors Expressed in the Brain
Julien Hanson |
| 11:35-11:55 | Influence of Adrenergic Receptors in Cell Viability of Glioblastoma Cell Lines Obtained from Mesenchymal and Classical Subtypes of Human Glioblastomas
Glória Queiroz |
| 11:55-12:15 | Discussion |

10:15-12:15 | MC2 Hall

Molecular Pharmacology of Cancer and Angiogenesis

Organized by the Hellenic Society of Basic and Clinical Pharmacology

Chairs: Evangelia Papadimitriou, Stavros Topouzis

- | | |
|-------------|---|
| 10:15-10:45 | Targeting vascular function to treat glioblastoma
Anna Dimberg |
| 10:45-11:15 | Targeting mitochondria to inhibit angiogenesis and treat cancer
Dr Stéphanie Herkenne |
| 11:15-11:45 | Non-coding RNAs as potential therapeutic targets in gut disease and cancer
Christos Polytarchou |
| 11:45-12:15 | Harnessing the potential of myeloid cells in liver cancer: a matter of genetics and combinations
Serena Vegna |

12:15-12:45 Lunch Break

12:45-13:45 Poster Session 1

13:45-15:45 | *MC3 Hall*

Targeting Molecular Networks for Drug Discovery

Organized by the Hungarian Society for Experimental and Clinical Pharmacology

Chairs: Peter Ferdinandy, Zsuzsanna Helyes

- | | |
|-------------|--|
| 13:45-14:15 | Importance of miRNA-mRNA networks for discovery and development of miRNA-therapeutics
Bence Ágg |
| 14:15-14:45 | Non-coding RNA molecular networks: Implications in drug discovery and diagnosis in the brain-heart axis
Yvan Devaux |
| 14:45-15:15 | Network Approaches for Charting the Transcriptomic and Epigenetic Landscape: Implications for target discovery
Jörg Menche |
| 15:15-15:45 | Network Pharmacology for Drug Repurposing
Harald Schmidt |

13:45-15:45 | *Trianti Hall*

De-risking Secondary Pharmacology Mediated Adverse Effects as a Path to Develop Safer Medicines

Organized by the British Pharmacological Society

Chair: Friedemann Schmidt, Jean-Pierre Valentin

- | | |
|-------------|---|
| 13:45-14:05 | Challenges, opportunities and state of the art considerations for in vitro and in silico secondary pharmacology profiling
Jean-Pierre Valentin |
| 14:05-14:25 | An IQ-DruSafe secondary pharmacology industry database analysis of current practices, experiences and recommendations for the future
Friedemann Schmidt |
| 14:25-14:45 | Translational Pharmacology Case Studies: Intricacies of predicting patient risk from in vitro secondary pharmacology data
Sonia Roberts |
| 14:45-15:05 | Analysis of Secondary Pharmacology Submissions to the US
Rebecca Racz |
| 15:05-15:25 | Translational Safety meets Pharmacovigilance
Jordi Mestres |

13:45-15:45 | *MC2 Hall*

Unravelling the Signaling Power of Pollutants

Organized by the Dutch Pharmacological Society & German Pharmacological Society

Chairs: Karim Rafie, Martina Schmidt

- | | |
|-------------|---|
| 13:45-14:15 | Role of TRP channels in the protection from and removal of pollutants in the lung
Alexander Dietrich |
| 14:15-14:45 | Receptors on the Move; The Convergence of Extracellular Vesicle and GPCR Biology
Caitrin Crudden |
| 14:45-15:15 | Imaging pollution - Using cryo-EM to elucidate the molecular events affecting beta-2AR signaling by pollutants
Karim Rafie |
| 15:15-15:45 | Alterations of microglia function and neuronal metabolism by pollutants: Impact for neurodegenerative disorders
Martina Schmidt |

15:45 - 16:15 Coffee Break

16:15-18:15 | *MC3 Hall*

The Ongoing Revolution on Anti-Obesity Pharmacological Therapies: Novel Perspectives and Potential Targets

Organized by the Italian Society of Pharmacology

Chairs: Mariarosaria Bucci, Adele Romano

- | | |
|-------------|--|
| 16:15-16:45 | Anti-obesity effects of oleoylethanolamide: from metabolic observations to the regulation of eating behaviour
Silvana Gaetani |
| 16:45-17:15 | "Amylin & Co." as aid for weight management: from the periphery to the central nervous system
Thomas Lutz |
| 17:15-17:45 | Dual agonists of the paracannabinoid and cannabinoid system as novel pharmacological tools to control metabolism
Fernando Antonio Rodriguez De Fonseca |
| 17:45-18:15 | Modifications in adipogenesis and remodeling of adipose tissue as potential strategies to overcome obesity
Antonio Vidal-Puig |

16:15-18:15 | Trianti Hall

Drug Discovery and Therapeutic Innovation for the Treatment of COPD

Chair: Clive Page

- 16:15-16:45 Novel drug targets in COPD
Ian Adcock
- 16:45-17:15 Ensifentrine, a novel bifunctional drug for the treatment of COPD
Clive Page
- 17:15-17:45 Early experimental medicine studies for investigating new drugs for COPD
Simon Pitchford
- 17:45-18:15 The burden of unmet needs in COPD
Wisla Wedzicha

16:15-17:45 | MC2 Hall

Alpha-Synuclein in Parkinson's Disease and Disease-Modifying Strategies for Non-Motor Symptoms

Organized by the Turkish Pharmacological Society

Chairs: Nezahat Tuğba Durlu-Kandilci, Leonidas Stefanis

- 16:15-16:45 Alpha synuclein as a therapeutic target in Parkinson's Disease and related synucleinopathies
Leonidas Stefanis
- 16:45-17:15 Modeling non-motor symptoms of alpha-synucleinopathy targeting autophagic pathway with rapamycin
Banu Cahide Tel
- 17:15-17:45 Uncovering a new molecular brake of neuronal plasticity: the role of nitric oxide and TRKB signaling
Caroline Biojone

18:15-19:00 Keynote | MC3 Hall

Chairs: Constantine Tamvakopoulos, Teresa Tejerina

Targeting of pathological ERK1/2 signaling
Kristina Lorenz

18:15-19:00 Keynote | Trianti Hall

Chairs: Vangelis Manolopoulos, Thomas Wieland

Hallmarks of GPCR Allosterism: Structure, Function and Beyond
Arthur Christopoulos

19:00-20:30 EPHAR Council Meeting | MC3.4 Hall

Tuesday, June 25, 2024

09:00-09:45 Keynote | MC3 Hall

Chairs: Peter Ferdinandy, George Liapakis

Efficacy and biased agonism at the Class B1 glucagon-like peptide-1 (GLP-1) GPCR

Patrick Sexton

09:00-09:45 Keynote | MC2 Hall

Chairs: Thomas Griesbacher, Constantine Tamvakopoulos

The expanding universe of gasotransmitters: physiology, pathophysiology and pharmacological applications

Csaba Szabo

09:45-10:15 Coffee Break

10:15-11:45 | MC3 Hall

Pharmacological Modulation of Autophagy in Aging and Neurodegenerative Diseases

Organized by the Italian Society of Pharmacology

Chairs: Agnese Secondo, Elisabetta Panza

10:15-10:45 Decoding molecular mechanisms linked to aging- and disease-related processes: a mitochondrial perspective
Daniele Bano

10:45-11:15 Pharmacological modulation of Lysosomal channels in ALS: new perspectives
Agnese Secondo

11:15-11:45 Autophagic mechanisms in ageing and neurodegeneration
Nektarios Tavernarakis

10:15-12:15 | Trianti Hall

Cannabis-Based Medicines for Inflammation – From Basic Concepts to Pre-Clinical Studies

Chairs: Nadine Godsmann, Cherry Wainwright

10:15-10:45 Molecular Targets for Anti-inflammatory Effects of Cannabidiol
Hang Ma

10:45-11:15 Cannabidiol and inflammation-resolving lipid Mediators
Franca Marino

11:15-11:45 Pre-clinical studies on CBD Oil and cardiac fibrosis
Nadine Godsmann

11:45-12:15 Pre-clinical studies on Cannabidiol and inflammatory pain
Karin Westlund-High

10:15-10:45 | MC2 Hall

From Regulators to Patients: The Journey of a Medicine in Greece

Chair: **Andreas Papapetropoulos**

From regulators to patients: the journey of a medicine in Greece

Georgios Panoutsopoulos

12:15-12:45 Lunch Break

12:45-13:45 Poster Session 2

13:45-15:45 | MC3 Hall

Natural Product Pharmacology

*Chairs: **Angelo Fontana, Robert Fuerst***

13:45-14:15 Immunotherapeutic Sulfur-containing Marine Natural Products
Angelo Fontana

14:15-14:45 Indispensable then and now - natural products as tools in drug research
Robert Fuerst

14:45-15:15 Metabolism and bioavailability aspects in bioactive natural products
Maria Halabalaki

15:15-15:30 Discovery of natural product derivative triptolidiol as a direct NLRP3 inhibitor by decreasing K63-specific ubiquitination
Ying Wang

15:30-15:45 A small natural molecule induces non-enzymatic NQO1-dependent necrosis in cancer cells through the JNK1/2/Iron/PARP/calcium pathway
Xiuping Chen

13:45-15:45 | Trianti Hall

Student-Centred Learning, Student Engagement and the Student Experience

*Chairs: **Betty Exintaris, Nilushi Karunaratne***

13:45-14:15 Engaging students through teamwork and inclusive practice
Nilushi Karunaratne & Betty Exintaris

14:15-14:45 Cognitive, emotional, and behavioural student engagement - how do we achieve them?
Paul White

14:45-15:15 Virtual reality animations in pharmacology education – student experience and perception of learning
Jon Andsnes Berg & Trond Trættemberg Serkland

15:15-15:45 Teaching about ethnicity in pharmacology - implications for the wider curriculum
Jennifer Koenig & Olusola Olafuyi

13:45-15:15 | MC2 Hall

Career Paths in Pharmacology

Organized by the Early Career Researcher Group of EPHAR

Chair: Kyriaki Thermos

- 13:45-14:15 Mining cysteinolysis in endothelial cell fates
Sofia-Iris Bibli
- 14:15-14:45 Tachykinin research: old family, new directions
Éva Borbély
- 14:45-15:15 It takes two to tango: pharmacology and passion
Patrycja Nowak-Sliwinska

15:45-16:15 Coffee Break

16:15-18:15 | MC3 Hall

Current Developments and Approaches in Ion Channel Pharmacology

Organized by the Swiss Society of Pharmacology and Toxicology

Chairs: Stephan Kellenberger, Stephan Von Gunten

- 16:15-16:45 Pharmacology and modulation of the P2X7 purinergic receptor channel
Annette Nicke
- 16:45-17:15 Using photoswitchable compounds to study the involvement of TREK channels in pain and migraine
Guillaume Sandoz
- 17:15-17:45 Development of ligand-gated ion channel drug screening assays across multiple automated patch-clamp platforms
Fitzwilliam Seibertz
- 17:45-18:15 Insights into the activation mechanism of acid-sensing ion channels (ASICs)
Stephan Kellenberger

16:15-18:15 | Trianti Hall

Exploiting Immunopharmacology in Different Diseases

Organized by the International Union of Basic and Clinical Pharmacology

Chair: Francesca Levi-Schaffer, Katerina Tiligada

- 16:15-16:45 Immunopharmacology in Cancer: Pharmacological targeting of mitochondrial metabolism in tumor-associated macrophages
Anna Brichkina
- 16:45-17:15 Immunopharmacology in Allergy: CD300a an inhibitory receptor expressed on inflammatory cells in allergy and beyond
Francesca Levi-Schaffer
- 17:15-17:45 Immunopharmacology in Asthma: Immunopharmacological interventions in treating asthma. Is it all about inflammation?
Emily Swindle
- 17:45-18:15 Immunopharmacology in Ocular Inflammation
Katerina Tiligada

Chairs: *Mariarosaria Buccì, Achilleas Gravanis*

16:15-16:30 OC01. E2F Transcription Factor 2 (E2F2) Facilitates Atherosclerosis Through CCAAT Enhancer Binding Protein β Mediated Endothelial Cell Inflammation

Wu Y¹, Huang X¹, Huang Y¹, Wang L¹

¹Department of Biomedical Sciences, City University of Hong Kong, Kowloon, China

16:30-16:45 OC02. Cyst(e)ine import and catabolism preserve endothelial chromatin accessibility and promote vessel growth

Mettner J^{1,2}, Drekolia M^{1,2}, Wittig J^{1,2}, Siragusa M², Weigert A³, Fleming I², Günther S⁴, Looso M⁴, Hecker D⁵, Schulz M⁵, Hu J^{1,6}, Bibli S^{1,2}

¹Department for Vascular Dysfunction, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, ²Institute for Vascular Signalling, Goethe University, Frankfurt, Germany, ³Institute for Biochemistry I, Faculty of Medicine, Goethe University, Frankfurt am Main, Germany, ⁴Cardio-Pulmonary Institute (CPI) Bioinformatics and Deep Sequencing Platform, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany, ⁵Institute for Cardiovascular Regeneration, Computational Epigenomics & System Cardiology, Faculty of Medicine, Goethe University, Frankfurt am Main, Germany, ⁶Department of Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

16:45-17:00 OC03. Investigating the cardioprotective potential of novel Sirtuin agonists. Sirtuin 5 emerges as a new target in mitigating myocardial ischemia-reperfusion injury

Castiello C¹, **Efentakis P**¹, Symeonidi L¹, Chania C¹, Tasouli A², Kostomitsopoulos N³, Mikros E⁴, Zwergel C⁵, Valente S⁵, Mai A⁵, Andreadou I¹

¹Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece, ²Onassis Cardiac Surgery Center, Athens, Greece, ³Biomedical Research Foundation of the Academy of Athens, Athens, Greece, ⁴Department of Pharmaceutical Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece, ⁵Department of Drug Chemistry and Technologies; University of Rome; Sapienza, Rome, Italy

17:00-17:15 OC04. Effect of SGLT2i on heart tissue in diabetic rats: SIRT1 connection

Kizrak U¹, **Özşarlak-Sözer G**¹, Shamamedov K¹, Alan-Albayrak E¹, Cilaker-Micili S², Cavdar Z³, Ural C³, Cetinkalp S⁴, Bilici-Guler G², Kerry Z¹

¹Ege University Faculty of Pharmacy Department of Pharmacology, Izmir, Turkey, ²Dokuz Eylul University, Faculty of Medicine, Department of Histology and Embryology, Izmir, Turkey, ³Dokuz Eylul University, Faculty of Medicine, Department of Molecular Medicine, Izmir, Turkey, ⁴Ege University, Faculty of Medicine, Department of Endocrinology and Metabolic Diseases, Izmir, Turkey

17:15-17:30 OC05. The functional interaction of Apolipoprotein A2 with the metabolic system of apolipoprotein E -rich- lipoproteins in the regulation of the lipid profile

Kakafoni G¹, Mparnia V¹, Giannatou K¹, Zvintzou E^{1,2}, Kypreos K¹, Gafencu A², Ioana Madalina F²

¹Pharmacology Laboratory, Department of Medicine, School of Health Sciences, University of Patras, Patras, Greece, ²Institute of Cellular Biology and Pathology "Nicolae Simionescu" of the Romanian Academy, Bucharest, Romania

- 17:30-17:45 OC06. Potential repurposing of the SYK inhibitor Fostamatinib in a diet-induced model of insulin resistance: an in vivo study**
Aimaretti E¹, Porchietto E², Ferreira Alves G², Einaudi G², Collotta D³, Rubeo C¹, Marzani E³, Mastrocola R¹, Cifani C², Aragno M¹, Collino M³
¹Department of Clinical and Biological Sciences, University of Turin, Turin, Italy, ²School of Pharmacy, University of Camerino, Camerino, Italy, ³Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy
- 17:45-18:00 OC07. Pharmacological inhibition of cyclin-dependent kinase 9 (CDK9) ameliorates metabolic abnormalities evoked by chronic consumption of hypercaloric diet in mice**
Porchietto E¹, Collotta D², Aimaretti E³, Ferreira Alves G¹, Einaudi G¹, Marzani E², Rubeo C³, Mastrocola R³, Aragno M³, Cifani C¹, Collino M²
¹Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy, ²Department of Neurosciences "Rita Levi Montalcini", University of Turin, Turin, Italy, ³Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
- 18:00-18:15 OC08. FKBP5 rs4713916 could serve as a genetic predictor of interindividual different response to inhaled corticosteroids in patients with chronic obstructive pulmonary disease**
Ntenti C¹, Papakonstantinou E³, Grize L², Stolz D², Goulas A¹
¹1st Laboratory of Pharmacology, Department of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, ²Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland, ³Clinic of Respiratory Medicine, Faculty of Medicine, University of Freiburg, Freiburg, Germany

18:15-19:00 Keynote | MC3 Hall

Chairs: Ioannis Charalampopoulos, Francesca Levi-Schaffer

Exploiting Mitochondrial Dysfunction for Cancer Therapy
Evripidis Gavathiotis

18:15-19:00 Keynote | MC2 Hall

Chairs: Maria Konstandi, Andreas Papapetropoulos

Selective protein degraders (PROTACs) as new pharmacological modalities and chemical tools for target validation
Stefan Knapp

Wednesday, June 26, 2024

9:00-10:30 Poster Session 3

10:00-10:30 Coffee Break

10:30-12:30 | MC3 Hall

Unraveling the Complexities of Systemic Inflammation: Insights from Sepsis, Trauma, and AI/Machine Learning

Organized by the European Shock Society and the Hellenic Institute for the Study of Sepsis

Chairs: Evagelos Giamarellos-Bourboulis, Borna Reija

- | | |
|-------------|---|
| 10:30-10:50 | Systemic Inflammation, Sepsis and Immunoparalysis; Inevitable or reversible?
Antigone Kotsaki |
| 10:50-11:10 | Trauma-Induced Systemic Inflammation - Friend or Foe?
Borna Relja |
| 11:10-11:30 | Molecular Profiling of Pneumonia and Sepsis using Machine Learning and AI
Brendon Scicluna |
| 11:30-11:50 | Pharmacological inhibition of CK2 with Silmitasertib protects against sepsis-induced cardiovascular dysfunction by interfering with nitric oxide release
Gustavo Ferreira Alves |
| 11:50-12:10 | Spleen Tyrosine Kinase: a novel pharmacological target for sepsis-induced cardiac dysfunction and multi-organ failure
Chiara Verra |
| 12:10-12:30 | Discussion |

10:30-12:30 | Trianti Hall

Pharmacological Landscape of Neuro-Immune Interactions: Insights and Implications

Organized by the American Society of Pharmacology and Experimental Therapeutics

Chairs: Habibeh Khoshbouei, Stephanie Matt

- | | |
|-------------|--|
| 10:30-11:00 | Role of dopamine on immune response and bone remodeling in rheumatoid arthritis
Silvia Capellino |
| 11:00-11:30 | The Role of Dopamine Transporter in Peripheral Immunity: Insights into Immune Cell Regulation
Habibeh Khoshbouei |
| 11:30-12:00 | Dopaminergic modulation of the immune response: lessons from Parkinson's Disease
Franca Marino |
| 12:00-12:30 | Antidepressant and Depression-mediated Myeloid Inflammation and HIV Viral Dynamics
Stephanie Matt |

10:30-12:30 | MC2 Hall

Chairs: **Ioannis Charalampopoulos Szaba Csabo**

10:30-10:45 OC09. The Role of DHEA(s) in Dementia: Insights from Cellular and Animal Models and Human Patients

Vuic B¹, Milos T¹, Tudor L¹, Konjevod M¹, Farkas V¹, Nikolac Perkovic M¹, Nedic Erjavec G¹, Knezovic A², Osmanovic Barilar J², Szabo A³, Farkas S³, Zelena D³, Uzun S⁴, Kozumplik O⁴, Mimica N⁴, **Svob Strac D**¹

¹Laboratory of Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, Zagreb, Croatia, ²Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia, ³Centre for Neuroscience, Szentágothai Research Centre, Institute of Physiology, Medical School, University of Pécs, Pecs, Hungary, ⁴Department for Biological Psychiatry and Psychogeriatrics, University Psychiatric Hospital Vrapce, Zagreb, Croatia

10:45-11:00 OC10. Dissecting the role of p75 pan-neurotrophin receptor in the hyperglycemia - induced neuropathology using a human iPSC-based model.

Chanoumidou K^{1,2}, Zota I^{1,2}, Papadopoulou M^{1,2}, Gravanis A^{1,2}, **Charalampopoulos I**^{1,2}

¹Pharmacology Dept., Medical School, University of Crete, Heraklion, Greece, ²Institute of Molecular Biology and Biotechnology of the Foundation for Research and Technology Hellas (IMBB-FORTH), Heraklion, Greece

11:00-11:15 OC11. The selective positive allosteric modulator (PAM) of the glutamate transporter EAAT2 efficiently relieves pain and pruritus of different origins and potentiates opioid-induced analgesia

Mogilski S¹, Kubacka M¹, Sapa J¹, Rapacz A¹, Jakubiec M², Abram M², Kamiński K²

¹Department of Pharmacodynamics, Faculty of Pharmacy, Medical College, Jagiellonian University, Kraków, Poland, ²Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland

11:15-11:30 OC12. Design and biological characterization of new biologic (Ab-IPL-IL-17) for IL-17s-mediated diseases

Saviano A¹, Mansour A², Raucci F¹, Merlino F³, Marigliano N¹, Schettino A¹, Vellecco V³, Cirino G³, Bucci M³, McGettrick H⁴, Grieco P³, Iqbal A², Maione F¹

¹ImmunoPharmaLab, Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy, ²Institute of Cardiovascular Sciences (ICVS), College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK, ³Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy, ⁴Institute of Inflammation and Ageing (IIA), College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

11:30-11:45 OC13. The anti-inflammatory cytokine IL-37 plus IL-15 enhances human NK cells anti-tumor functions by interacting with IL-1R8

Landolina N¹, Mariotti F¹, Pelosi A¹, D'Oria V², Ingegnere T¹, Alicata C¹, Vacca P³, Moretta L¹, Maggi E¹

¹Tumor Immunology Unit, Bambino Gesù Children's Hospital, IRCCS 00146 Rome, Italy, ²Research Laboratories, Confocal Microscopy Core Facility, Bambino Gesù Children's Hospital, IRCCS, 00146 Rome, Italy, ³Immunology Research Area, Innate Lymphoid Cells Unit, Bambino Gesù Children's Hospital, IRCCS, 00146 Rome, Italy

11:45-12:00 OC14. Crizotinib inhibits mTORC1 activation, protein synthesis and endothelial cell activation by pleiotrophin or PTPRZ1 deletion

Mourkogianni E¹, Ntenekou D¹, Enake M¹, Xanthopoulos A¹, Kastana P¹, **Papadimitriou E**¹

¹University of Patras, Patras, Greece

12:00-12:15 OC15. Observational studies of repurposing old drugs for new indications: The example of metformin to treat breast cancer

Suissa S^{1,2}

¹McGill University, Montreal, Canada, ²Jewish General Hospital, Montreal, Canada

12:15-12:30 OC16. Emerging roles of 3-MST in colon cancer

Ascencio K¹, Szabo C¹

¹University of Fribourg, Fribourg, Suisse

13:00-14:00 Paoletti Award Speech | *Trianti Hall*

Chairs: Giuseppe Cirino, Maria-Jesus Sanz

Reprogramming the synapse: from basic findings to translational research

Monica DiLuca

14:00-15:30 Closing Ceremony | *Trianti Hall*

Gold Sponsors



Silver Sponsors



Supporters



Sponsors



WinMedica



nanji[on



*Lab Supplies
Scientific*



Exhibitors



ΤΟ
ΚΛΙΚ ΤΗΣ
ΕΜΠΙΣΤΟΣΥΝΗΣ^{1,2*}



Trimbow

συσκευή εισπνοής

NEThaler

ΤΟ ΚΛΙΚ ΤΗΣ ΕΜΠΙΣΤΟΣΥΝΗΣ^{1,2*}

1. Trimbow® συσκευή εισπνοής NEXThaler® ΠΧΠ
2. Voshaar T. et al. J Aerosol Med Pulm Drug Deliv. 2014;27(5):363-370

*Το «ΚΛΙΚ» σχετίζεται με την ενεργοποίηση της συσκευής εισπνοής NEXThaler®, το οποίο επιβεβαιώνει στους ασθενείς ότι η πλήρης δόση έχει απελευθερωθεί² και δεν αποτελεί διαβεβαίωση ορθής λήψης της δόσης από τον ασθενή.

Οι αντενδείξεις, οι προφυλάξεις και οι ανεπιθύμητες ενέργειες περιλαμβάνονται στην ΠΧΠ του προϊόντος. Για την Περίληψη Χαρακτηριστικών του Προϊόντος πατήστε **εδώ**




CHIESI HELLAS A.E.B.E.
Πλ. Γερουλάνου & Ρένου Πόγγη 1,
Τ.Κ.: 174 55, Άλιμος Αττικής, Ελλάδα
Αρ. ΓΕΜΗ 002669501000
Τ.: +30 210 61 79 763, F.: +30 210 61 79 786
E.: chiesihellas@chiesi.com,
E. τμήματος φαρμακοεπαγρύπνησης: pharmacovigilance.gr@chiesi.com
www.chiesi.gr

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή
και Αναφέρετε:
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»



Verduci Editore

J O U R N A L S



Since 1970, Verduci Editore has been a leading force in sharing medical-scientific knowledge globally.

As a pioneering publishing house, we specialize in creating encyclopedic treatises, comprehensive manuals, and esteemed international open-access journals.

Join us in advancing global health and knowledge.

Scan the QR code for more information about our books and journals



www.verduci.it



info@verduci.it



Via Gregorio VII, 186 - 00165 Roma



+39 06 39375224



Biomedcode
Priming drugs for success

Priming Drugs for Success


We specialize in preclinical testing using mouse disease models with humanized therapeutic targets

Therapeutic Areas

- Acute Inflammation
- Arthritis
- Cancer
- Fibrosis
- Infectious Diseases
- Inflammatory Bowel Disease
- Lupus
- Multiple Sclerosis
- Osteoporosis
- Psoriasis
- Spondyloarthritis



Humanized Targets



CRO Preclinical Services

- In vivo efficacy studies
- In vitro screening
- Ex vivo testing
- PK/PD studies

Analysis Methods

- Histology
- Molecular assays
- Cellular assays
- Immunoassays
- Immunophenotyping



Our clients around the world